ArticleRSC advances2026
Anisotropic gold nanochains with dual-ligand interfaces for theranostic immune activation.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-dependent cellular cytotoxicity (ADCC) represents a key mechanism of cancer immunotherapy, yet conventional antibody-nanoparticle systems often suffer from limited Fc accessibility, random ligand orientation, and short circulation stability. To overcome these limitations, we developed a modular gold nanochain platform through end-to-end assembly of alkyne- and azido-functionalized gold nanorods using click chemistry. Each nanorod unit was selectively modified with folic acid or immunoglobulin G (IgG) Fc fragments to achieve spatially segregated tumor-targeting and immune-engaging functionalities. The resulting polyethylene glycol (PEG)-linked nanochains exhibited tunable length, excellent colloidal stability, and characteristic plasmonic coupling, enhancing both surface-enhanced Raman scattering (SERS) and near-infrared absorption. Cellular studies using folate receptor-positive KB cells confirmed receptor-mediated uptake and selective binding, while ADCC assays demonstrated significantly enhanced natural killer (NK) cell-mediated cytolysis compared to single nanorods and even the monoclonal antibody control (Herceptin). Mechanistically, the elongated morphology and multivalent Fc presentation facilitated stable immune synapse formation and improved effector cell recruitment. Collectively, this study establishes a versatile and biocompatible nanochain platform that integrates cancer targeting, immune activation, and optical imaging within a single construct, offering a promising direction for next-generation immunotheranostic nanomedicine.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.